Brefeldin A

Catalog No.S7046

Brefeldin A  Chemical Structure

Molecular Weight(MW): 280.36

Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.

Size Price Stock Quantity  
In DMSO USD 80 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

1 Customer Review

  • Cells were treated with brefeldin A or manumycin A, and the resulting supernatant was collected after 48 h for exosomal preparation (lanes 1 and 2), or exosomes obtained from C81 cells were trypsin-treated or freeze/thawed (F/T) and then trypsin-treated (lanes 3 and 4). Lanes 5 and 6, input exosome controls from C81 or CEM cells, respectively. Resulting exosomes were assayed for the presence of Tax by Western blotting.

    J Biol Chem, 2014, 289(32):22284-305.. Brefeldin A purchased from Selleck.

Purity & Quality Control

Choose Selective ATPase Inhibitors

Biological Activity

Description Brefeldin A is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis.
Targets
ATPase (HCT 116) [1]
0.2 μM
In vitro

Brefeldin A is a fungal metabolite and blocks the forward transport between the endoplasmic reticulum and Golgi apparatus, Brefeldin A causes an impaired distribution of the membrane proteins. When HCT 116 human colon cancer cell is treated with Brefeldin A, morphological changes indicating cell differentiation are observed. Brefeldin A exerts its cytotoxic effects mainly by inducing differentiation and apoptosis in tumor cells. [1] The treatment of the strips with 20 μg/mL Brefeldin A for 6 hours completely abolishes the relaxation induced by bradykinin in the presence of 10mM indomethacin and 30 μM L-NOARG. The treatment with 20 μg/mL Brefeldin A substantially abolishes the bradykinin-induced decreases in [Ca2+]i and tension in the range of concentrations between 1 nM and 1 mM. Brefeldin A has no effect on the [Ca2+]i elevation in endothelial cells induced by bradykinin or substance P. [2] Addition of the fungal metabolite Brefeldin A does not affect the spontaneous phospholipid-dependent GTPS binding to myr-rARF1 but totally abolishs the retinal isotonic extract (RIE)-catalyzed exchange, with half-maximal inhibition at 2 μM Brefeldin A. Brefeldin A prevents a wide variety of membrane traffic pathways. Brefeldin A inhibits an ADP-ribosylation factor-specific guanine nucleotide exchange activity present in Golgi membranes or in brain cytosol. The complete prevention by Brefeldin A strongly suggests that the retinal extract contains an ARF-specific guanine nucleotide exchange factor. Retinal isotonic extract (RIE)-catalyzed GTPS release from both ADP-ribosylation factors (ARFs) is only partly inhibited by Brefeldin A, even at 300 μM. [3] Brefeldin A induces fusion of the Golgi apparatus with the ER. Brefeldin A abolishes the inhibitory effect of the CERT inhibitor HPA-12. Brefeldin A treatment, which induces fusion of the Golgi apparatus and the ER, rescues the limonoid-induced prevention of sphingomyelin biosynthesis. BFA treatment of CHO cells causes a 2 to 3 fold increase in sphingomyelin synthesis. [4] Apart from B-CLL cells, Brefeldin A reportedly causes apoptosis in multiple myeloma (U266, NCI-H929), Jurkat, HeLa, leukaemia (HL60, K562, BJAB), colon (HT-29) and prostate, as well as adenoid cystic sarcoma cells. The administration of 25 ng/mL of Brefeldin A completely blocks growth of HF4.9 and HF28RA cells, whereas higher Brefeldin A doses (75 ng/mL) are required to achieve the same effect in HF1A3 cells. Cell proliferation is inhibited within 24 hours in a dose-dependent manner and, depending on the cell line, almost complete cessation of 3H-thymdine incorporation is observed at 50-75 ng/mL of Brefeldin A (26%, 76%, 87% inhibition at 50 ng/ml and 75%, 87%, 92% inhibition at 75 ng/mL for HF1A3, HF4.9 and HF28RA cells respectively. Brefeldin A-induced cell killing is in a dose-dependent manner using YO-PRO 1/PI assay. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PC12 MYPGeY5kfGmxbjDBd5NigQ>? MWCyJO69VQ>? MVixJIg> MWPpcohq[mm2czD0bIUhVC2GT2DBJEgzOMLizszNLU1qdmS3Y3XkJJRz[W6|aXXueEBGWktzL{KgdIhwe3Cqb4L5cIF1cW:wwrC= NHH2bXozPjN4M{G5NS=>
C2C12 MkXOSpVv[3Srb36gRZN{[Xl? NF\NPGMyyqEQvHevcYw> M2X0SlHDqGh? MmL6ZYJwdGm|aHXzJIN6fG:taX7lJJJmdGWjc3Wg[pJwdSCFMlOxNkBugW:2dXLldy=> MlraNlYzQTF{N{m=
MEFs WT MXLGeY5kfGmxbjDBd5NigQ>? NIXqXGg2yqEQvF2= M2X4eVIxKG2rbh?= MV;jZZV{\XNicnXzbYRmdnRiZX76fY1meyC|dXPoJIF{KE6DR2StS2ZRNCC2bzDkbYZnfXOnIHLhZ4shfG9idHjlJGVT MoDENlYyQTZyMkO=
MEFs VAMP7 KO MkThSpVv[3Srb36gRZN{[Xl? NXnMRXRCPcLizszN M1rUXFIxKG2rbh?= NGXvV2Rk[XW|ZYOgdoV{cWSnboSg[Y57gW2nczDzeYNpKGG|IF7BS3QuT0[SLDD0c{BlcW[odYPlJIJi[2tidH:geIhmKEWU M17jbVI3OTl4MEKz
SMCs MWfGeY5kfGmxbjDBd5NigQ>? MYOxNOKhyrWpL33s NFzmfXoxNTF{IHi= NG\ETHpFVVOR MW\zbI94eyCjIITy[Y5lKHSxd3Hy[JMh[SCqaXfo[ZIh[2:wY3XueJJifGmxbjDv[kB1cGViRWKvV3IhdmW2d3;yb{BqdiC2aHWgdIVzcW63Y3zlZZIh[XKnYdMg NWrVO5NWOjZzN{KwPFA>
SMCs NWnWZlA{TnWwY4Tpc44hSXO|YYm= NWrwNIJtOTEEoNM1[{9udA>? NGPUTZQxNTF{IHi= NH24O4JFVVOR NEXF[Ihk[XW|ZYOgZUB1emGwc3nlcpQhS2F{K9MgdoVt\WG|ZTDmdo9uKHSqZTDFVk9UWsLi MoXaNlYyPzJyOEC=
HEMC-1 NVn1ZpRHTnWwY4Tpc44hSXO|YYm= MUiwMlHDqML3Zz;tcC=> M1TuTFI1yqCq MXrjZZV{\XNiYTDobYdp\XJiaX7obYJqfG:{eTDl[oZm[3Rib36g[Zhw[3m2b4Ppd{B1cGGwIH7vZ49l[XqxbHW= NXHYfod2OjV7N{K3OVk>
HUVEC M1HGNmZ2dmO2aX;uJGF{e2G7 MXmxNOKh|ryP M{P0OlHDqGh? MX;EUXNQ M3vpXYFjd2yrc3jld{BpgXCxeHnhMYlv\HWlZXSgdoVt\WG|ZTDv[kBCXFBiZoLvcUBieGmlYXygZY5lKGKjc3;sZZRmemGuIIP1doZi[2W| NX3PT5dsOjV7NU[5PFg>
HUVEC M3\iTWZ2dmO2aX;uJGF{e2G7 MnzoNVDDqM7:TR?= MnrxNeKhcA>? NEn2S4dFVVOR NHnUPGtqdmO{ZXHz[ZPDqHSqZTDueY1j\XJiYX7kJIlvfGWwc3n0fUBw\iCobIXvdoV{[2WwdDDhdoVieyCnc4DlZ4lidGy7IHnuJJBmemmwdXPs[YFzKHOyYXPl NX:5eW14OjV7NU[5PFg>
Caco-2 MX3GeY5kfGmxbjDBd5NigQ>? NX7Qemc5Oi53IN88US=> NUHPdHEzOzBibXnu NITtWVVifHSnboXheIV{KHSqZTDUS2Yu|rJzLX3l[IlifGWmIHnuZ5Jm[XOnIHnuJHNGWlRiZoXuZ5Rqd25? NITiPZYzPTl3NEmzNS=>
NRK NHHiVVZHfW6ldHnvckBCe3OjeR?= NUfObJNtOjBy4pEFcocwdWx? NEDrb2816oDHaB?= M{fxWGROW09? M1j1N5Jme2O3ZYOgcYl1d3SrYzDwdo9oemW|c3nvci=> NGj4NpEzPTl2OEW4Oi=>
HeLa Mk\0SpVv[3Srb36gRZN{[Xl? NUXXVHpJOjBy4pEFcocwdWx? NXPifFgyOyCq MYXEUXNQ MYXpcoR2[2W|IITo[UBienSrZnnjbYFtKGK{ZXHrMZVxKG:oIITo[UBId2ypaTDjc41xdGW6 MmPDNlU6PDh3OE[=
COS NXvOeJd5TnWwY4Tpc44hSXO|YYm= NG\ZS3AyKM7:Zz;tcC=> M3fNcVMhcA>? NEHoZpVkd22ybHX0[Yx6KGSrc4DldpNmeyC2aHWgRXAuOSC|aXfuZYzDqA>? Mof0NlU6OTV7MEC=
DF1  MmnkSpVv[3Srb36gRZN{[Xl? MnHLNeKh|ryPwrC= NHTjTIE1QCCq NWDUSYxpTE2VTx?= NHzFWXJlcXOyZYLz[ZPDqHSqZTDlfI9o\W6xdYOgR3NI[WyQQXPUNkBxem:2ZXnu MnztNlU5ODdyNUS=
nHDFs  MV\GeY5kfGmxbjDBd5NigQ>? NVSzclNXOcLizszNxsA> MlH3NuKhcA>? MmS3dJJmfmWwdIOgeIhmKGG|c3XtZox6KG:oIHP5eI9{d2yrYzDjc4F1KHC{b4TlbY5{KG:wdH:gS49t\2libXXtZpJidmW| NX\TZ|RLOjV5N{K2NVY>
FRT  M2jmcGZ2dmO2aX;uJGF{e2G7 MnPWOUDPxGdxbXy= NGXvdWIzyqCq MYPicI9kc3NidILh[oZq[2urbnegeIhzd3WpaDD0bIUhT2:uZ3mgZ49ueGyneDDifUBqdmirYnn0bY5oKEWULYTvMWdwdGerIITyZY5{eG:{dB?= M3TIPVI2PzZ5MUG1
FRT  M3\SeWZ2dmO2aX;uJGF{e2G7 MmnqOUDPxGdxbXy= NGHjOWwzyqCq NF\1V2ZxemW4ZX70d{B1cGViaX7jdoVie2ViaX6gZ4xm[X[nZDFOtUB{fWK3bnn0d{B4cGWwIGvOZUteccLid3HzJJJm\HWlZXS= MkC5NlU4PjdzMUW=
HepG2  M3n5WGZ2dmO2aX;uJGF{e2G7 NUjCVVRROeLCidM1UeKh NGG2fXAzPCCq NHLoOoxFVVOR NV\4UZk{\GWlcnXhd4V{KHSqZTDs[ZZmdCCxZjDQXHIhdVKQQR?= NVf6dpd2OjV4MU[1PVc>
SMCs M3nKcWZ2dmO2aX;uJGF{e2G7 NX3rT3NxOc7:Zz;tUC=> NFTUU5E{KGh? MlL3ZYNkfW23bHH0[ZMhS06SWUKgdJJwfGWrbjDpckB1cGViRWKgZ49ueGG{dH3lcpQh[W6mIH7vJIxwdmencjDjc{1td2OjbHn6[YQhf2m2aDD0bIUhT2:uZ3mgcYFzc2W{wrC= MX2yOVU5QTR{NR?=
OB-6 MYjBdI9xfG:|aYOgRZN{[Xl? M2SwU|IvP8LizszN NEGxd4w1QCCq MkDKbY5lfWOnczDhdI9xfG:|aYO= MXGyOVU{OjR6MB?=
iPSC-CMs  NH;Tfo9HfW6ldHnvckBCe3OjeR?= NH7PdXQ2ODBibnevcYw> M4exUFQ5KGh? MkDrbY5kemWjc3XzJJRp\SCrboTlcpNqfHlib3[geIhmKGirZ3jldkBud2KrbHn0fUBNSU2SczDheEB1cGViY3;zeEBw\iC2aHWgcI94\XJibX;ibYxqfHlic4DlZ4lmew>? Mnq2NlU1QDh4Nk[=
SP-Nluc NVnYe2t[TnWwY4Tpc44hSXO|YYm= MXO1JI1oN22O MlLsOkBp MknISG1UV8Li M4rq[YNifXOnczDhckBqdmO{ZXHz[UBqdiC{ZYDvdpRmeiCjY4Tpeol1gSCrbjD0bIUheGG{YYPpeIU> MU[yOVM6Ojl7OB?=
PEXEL-Nluc M3HN[2Z2dmO2aX;uJGF{e2G7 NHvtTYc2KG2pL33M NEi3PJo3KGh? MWHEUXNQyqB? NXfFcJk4[2G3c3XzJIFvKGmwY4LlZZNmKGmwIILldI9zfGW{IHHjeIl3cXS7IHnuJJRp\SCyYYLhd4l1\Q>? NEHCRZkzPTN7Mkm5PC=>
H1299 MnzjSpVv[3Srb36gRZN{[Xl? Ml63NVAh|rypL33s MYGyOEBp NFL5UYlqdmS3Y3XzJIF2fG:yaHHnfeKh NUDvOXF{OjV|OEi5O|A>
MDA-MB-231 NIjPZY1E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NHfP[Gkx6oDVNUCg{txoN22O MmjWOFghcA>? M2TaVWVEPTEEoE2gNE4xOTZiwsXnM41N MkTUNlU{PTZ3Nke=
MDA-MB-231 M4SyS2Fxd3C2b4Ppd{BCe3OjeR?= M2W1elAvOSEQvHevcWw> M2HkVlQhcA>? MY\pcoR2[2W|IHHwc5B1d3Orcx?= MUOyOVM2PjV4Nx?=
MDA-MB-231 NWW1XXQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f4[lAvODFxMD6wOUDPxGdxbVy= MYeyOEBp NXmxTYw6cW6lcnXhd4V{KHSqZTDmdoFkfGmxbjDv[kB{fWJvR{GgZ4VtdCCmZXLybZM> M1TXblI2OzV4NU[3
MDA-MB-231 NH2y[mNCeG:ydH;zbZMhSXO|YYm= NIDyRnAxNjB34pETNUDPxGdxbVy= MmT1NlQhcA>? M{\sTYlv\HWlZYOgVGFTWCBqcH;sfUBCTFBvcnnic5NmKHCxbInt[ZJie2VvMTmgZ4xm[X[jZ3W= MnfPNlU{PTZ3Nke=
MDA-MB-231 MV;GeY5kfGmxbjDBd5NigQ>? MVGw5qCUPTBizsznM41N M{HJ[VI1KGh? MVjpcohq[mm2czD0bIUh\m:{bXH0bY9vKG:oIEPEJIFv\CB{RDDjc4xwdmmncx?= NFjtOm0zPTN3NkW2Oy=>
A172 MWLGeY5kfGmxbjDBd5NigQ>? NIDwe5oyOMLizsznM41t NVXwT2s4PMLiaB?= MmXBSG1UV8Li NHvNOlVz\XO3bITzJIlvKHSqZTDy[ZRzd2e{YXTlJJRz[W6|cH;yeEBw\iCobIXvdoV{[2WwdDDndoFvfWyncx?= NWW3VHhmOjV{M{m1NFc>
KMS-6 MUHGeY5kfGmxbjDBd5NigQ>? MoHRNeKh|ryPwrC= NGr3N2EzPCCq MkK2[ZhpcWKrdIOgbIFt\iC2aHWgd4VkemW2aX;uJI9nKGejbHHubY4uVEliYYOg[IllKHSqZTDjc451em:u NHfSNG0zPTJ{OUGyOi=>
MEC MnO4SpVv[3Srb36gRZN{[Xl? MkXhNUDPxE1? NV64OY9YOS53IHi= NYTtbGNr[2G3c3XzJIEh\HKjbXH0bYMh\GWlcnXhd4UhcW5idHjlJJN2em[jY3WgWmVITlJ{ NHvxNmQzPTJ{OEixOS=>
HEK293/hERG MVHGeY5kfGmxbjDBd5NigQ>? M4G5[lExyqEQvF2= Mnm2NeKhcA>? NXOxe3JiemW|dXz0d{BqdiCjIITpcYUu\GWyZX7k[Y51KHKnZIXjeIlwdiCvYYT1doUhcEWURzDwdo91\WmwwrC= MX:yOVIyQDR4OR?=
RBE4 M3y5NGFxd3C2b4Ppd{BCe3OjeR?= MVeyxsDPxE1? Mnm0N-KBmzJ2wrDo MlzubY5lfWOnczDhdI9xfG:|aYOgeIlu\SCmZYDlcoRmdnSueR?= MlflNlUyOjhyMkW=
RBE4 NXT4OYV1TnWwY4Tpc44hSXO|YYm= MlvzNuKh|ryP M1LIRVPjiJN{NNMgbC=> M1f3d4lv[3KnYYPld{B1cGViWFLQNUBxem:2ZXnuJIxmfmWuczDh[pRmeiB|IHHu[EA3yqCqIH;mJJRz\WG2bXXueC=> M33INlI2OTJ6MEK1
RBE4 MmO1SpVv[3Srb36gRZN{[Xl? NH3M[HMzyqEQvF2= NFzmV2Q{6oDVMkVCpIg> MX;pcoNz\WG|ZYOgZYN1cX[nIHPhd5Bie2VvMUKgbY4h[SC2aX3lMYRmeGWwZHXueEBu[W6wZYNCpC=> MnnzNlUyOjhyMkW=
RBE4 MmrFSpVv[3Srb36gRZN{[Xl? M4fNPVLDqM7:TR?= NU\ZNoNqO+LCk{K0xsBp M4\qTolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIGLPV{B1cW2nLXTldIVv\GWwdHz5 MoHyNlUyOjhyMkW=
RBE4 M4LUXGZ2dmO2aX;uJGF{e2G7 M4PzNVLDqM7:TR?= M{O1SFPjiJN{NNMgbC=> NY\WTYQ5cW6mdXPld{BiKGSnbHH5[YQh\GWybHX0bY9vKG:oIITo[UBGWiCFYUKrxsBkd262ZX70JIF1KDcEoHigc4YhcW6ldXLheIlwdiC|aXfubYZq[2GwdHz5 Ml7uNlUyOjhyMkW=
RBE4 Mm\OSpVv[3Srb36gRZN{[Xl? NGfNS3MzyqEQvF2= NX7K[oNjO+LCk{K0xsBp NGfG[5pqdmS3Y3XzJIFvKG:4ZYLsc4FlKG:oIFPhNkvDqGmwIITo[UBucXSxY3jvcoRzcWFiaX6geIhmKG[rcoP0JFbDqGhib3[gbY5kfWKjdHnvckApeOLCiU|ihKkxNjByMTmgZpV1KEOjMjxCpIxmfmWuczDpckB1cGm|IH;y[4Fv\WyuZTDk[YNz\WG|ZXSgZYZ1\XJiMUNCpIghd2ZiaX7jeYJifGmxbh?= MmfTNlUyOjhyMkW=
Huh-7  MXnGeY5kfGmxbjDBd5NigQ>? M1XSRVHPxGdxbVy= NHP5dIU{6oDVMkVCpIg> MlTwbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCDUFWxJIlvKGFidHnt[U1l\XCnbnTlcpQhdWGwbnXy NXzJbnNjOjVyMk[xO|Q>
HepG2  M1q0fGZ2dmO2aX;uJGF{e2G7 NEDxOJky|rypL33M NI\TUFk{6oDVMkVCpIg> M2nrOolv[3KnYYPld{B1cGVibHX2[Ywhd2ZiQWDFNUBqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> MUCyOVAzPjF5NB?=
H838-LKB1 M{PWVWZ2dmO2aX;uJGF{e2G7 M2HVWFMxyqCwZz;tcC=> Mn7qNVIwOThiaB?= MoHlbY5kemWjc3XzJJRp\SCycn;0[YlvKGyndnXsd{Bw\iCEaWFCpC=> NHv5XoszPTBzMUC4Ni=>
H838-KDLKB1  MXXGeY5kfGmxbjDBd5NigQ>? M{PYWlMxyqCwZz;tcC=> NUfzblZzOTJxMUigbC=> NWXOcIF[cW6lcnXhd4V{KHSqZTDwdo91\WmwIHzleoVteyCxZjDCbXDDqA>? NH\aU|MzPTBzMUC4Ni=>
H838-KDLKB1  Mn3DSpVv[3Srb36gRZN{[Xl? NYG2[XRIOzEEoH7nM41t M2fUWlEzNzF6IHi= M3S3PYlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIIDoc5NxcG:{eXzheIVlKGWLRkNOtUApeGixc4Doc{1mUUZ{zsGp MV:yOVAyOTB6Mh?=
3T3-L1 M3vXNmZ2dmO2aX;uJGF{e2G7 MVK1JO69\y:vbB?= NF;nc3I{OCCvaX6= MYjtbY1q[3NidHjlJIVn\mWldIOgc4YhcW6|dXzpckBidmRiY3H1d4V{KHKxYoXzeEBxcG:|cHjvdplt[XSrb36gc4YhSWu2IDjT[ZIhPDd|KTDhcoQheGixc4Doc5J6dGG2aX;uJI9nKEGVMU[wJEhVcHJiNkSyJIFv\CCVZYKgOVg5MQ>? NH;vSXQzPDh2M{iyOy=>
3T3-L1 NWjWPINOTnWwY4Tpc44hSXO|YYm= M1HFN|Uh|rypL33s MV:zNEBucW5? NUHJPWNPemWlYYDpeJVt[XSnczDpcpN2dGmwIHHjeIlwdiC5aYToJJJme3CnY4SgeI8hemWpdXzheIlv\yCDa4SgZYN1cX[rdImgZY5lKEGVMU[wJJBpd3OyaH;yfYxifGmxbh?= NFXwdpozPDh2M{iyOy=>
3T3-L1 M1fNVGZ2dmO2aX;uJGF{e2G7 NVi4cIE6PSEQvHevcYw> NVLrNndZOzBibXnu MVjjZZV{\XNicnX2[ZJ{cWKuZTDy[YRqe3S{aXL1eIlwdiCxZjDHUHVVPA>? MnjCNlQ5PDN6Mke=
3T3-L1 NHznN3BHfW6ldHnvckBCe3OjeR?= NHnJNYw2KM7:Zz;tcC=> NIC3bmoyyqCq MX3jZZV{\XNicnXkbZN1emmkdYTpc44hd2ZiR1zVWFQh[nW2IH7veEBqdmO{ZXHz[UBqdiCpbIXjc5NmKHWydHHr[S=> MoLONlQ5PDN6Mke=
3T3-L1 NYjUXY1CTnWwY4Tpc44hSXO|YYm= NHvRRZc2KM7:Zz;tcC=> M4jEXlHDqGh? MnzKZ4F2e2W|IIDoc5NxcG:{eXzheIlwdiCxZjD0bIUhTm:6T{GgeJJidnOlcnnweIlwdiCoYXP0c5I> MUmyOFg1Ozh{Nx?=
HeLa  NInSNnRHfW6ldHnvckBCe3OjeR?= NYLNd4lyPSEQvHevcYw> MVSzJIg> MULjZZV{\XNiboXjcIVieiCneHPseZNqd25ib3[geIhmKE[xeF:xJJRz[W6|Y4LpdJRqd25iZnHjeI9zKGGwZDDk[YNz\WG|ZYOgeJJidnOlcnnweIlwdiCxZjDGc5hQOS2{ZXf1cIF1\WRiZ3Xu[ZM> M4XEO|I1QDR|OEK3
HEK293 M{[5V2Z2dmO2aX;uJGF{e2G7 NWjQXmFxPcLizsznM41t NHTpdoIyOsLiaB?= NWn2e3JT[WKxbHnzbIV{KEOPQT3pcoR2[2WmIFPSSWxFOiC|ZXPy[ZRqd25? MYCyOFY5PzR|MR?=
COS-1 NEOzT2JHfW6ldHnvckBCe3OjeR?= NXSzRY9tPSEEtXevcYw> Mof0NlQhcMLi MYDy[ZN1emmldIOgcI9k[WyrenH0bY9vKG:oIF7CJIlvKHSqZTDw[ZJqdnWlbHXhdkBz\Werb39CpC=> M17pbVI1PjdzN{Wx
PRP MX3GeY5kfGmxbjDBd5NigQ>? NUH5[4dQOTBizszN MWHhZpJw\2G2ZYOgV2RHNTIQsT3t[YRq[XSnZDDDXGNTPyCneITldo5idGm8YYTpc47DqA>? NVzvPVZqOjR4Nki3OVA>
RAW264.7 NHPobIZCeG:ydH;zbZMhSXO|YYm= MlrjOEDPxE1? NIiyTJQ1QCCq NF32R4lifHSnboXheIV{KHSqZTDpcohq[mm2aX;uJI9nKG:6LVzEUE1qdmS3Y3XkJIFxd3C2b4Ppd{BidmRidHjlJIZi[2muaYTheIlwdiCxZjDjbI9t\XO2ZYLvcEBm\m[udYigZpkhSWNvaFWtNVhCNU6KMh?= NFjDRXEzPDZ|OUCzNi=>
MDMs MoH2RZBweHSxc3nzJGF{e2G7 M2DoVFEx6oDLzsznM41t MlTrNVIwOTViaB?= M4XXO4lv\HWlZYOgZZBweHSxc3nz MmDCNlQ2PTZ4OUW=
PMHs  NHTGdIVHfW6ldHnvckBCe3OjeR?= MVexNQKBmzJy4pEJ{txoN22u M1HGPFI16oDLaB?= MV7EUXNQ MYnpcoR2[2WmIFXSJJN1emW|cx?= Ml\UNlQ1ODd{NEK=
PMHs  NITKVJFCeG:ydH;zbZMhSXO|YYm= MoPSNVDjiJN{MPMAje69\y:vbB?= NHP4OIgzPOLCiXi= M3vY[2ROW09? NIrvOHRqdmO{ZXHz[ZMh[2WubDDk[YF1cA>? Mn;tNlQ1ODd{NEK=
HEK293/tau M2rjU2Z2dmO2aX;uJGF{e2G7 NWPkPHc4PSEQvF2= M4jKPVEwOi92IHi= Mne1bY5lfWOnczDHc4xocSCocnHncYVvfGG2aX;uxsA> MXmyOFM3QDB6OR?=
HEK293/tau NIe5fIpHfW6ldHnvckBCe3OjeR?= MXm1JO69VQ>? NX;z[XFROyCq NXrN[XY1cW6mdXPld{B1[XViaInw[ZJxcG:|cHjvdplt[XSrb36= NIPwTo4zPDN4OEC4PS=>
ADF NWjQelN{TnWwY4Tpc44hSXO|YYm= MUCxNEDPxE1? NIXS[JIyPiCq M{Sz[YlvcGmkaYTzJJRp\SCcblPsNk1qdmS3Y3XkJJRz[W6|bH;jZZRqd25ib3[gR3JV M2e4blI1OjJ6MkOy
U373  MW\GeY5kfGmxbjDBd5NigQ>? NHnGZo8yOCEQvF2= NHLnSmwyPiCq MX;pcohq[mm2czD0bIUhYm6FbEKtbY5lfWOnZDD0doFve2yxY3H0bY9vKG:oIFPSWC=> NYLibIVvOjR{MkiyN|I>
RKO-HIPK2i MUPGeY5kfGmxbjDBd5NigQ>? M3nyPVExKM7:TR?= NUHwW3dqOTZiaB?= M1X2e4lvcGmkaYTzJJRp\SCcblPsNk1qdmS3Y3XkJJRz[W6|bH;jZZRqd25ib3[gR3JV M{TwbVI1OjJ6MkOy
ADF  MmPjSpVv[3Srb36gRZN{[Xl? MVyxNEDPxE4EoB?= NEnw[Wc3KGh? NGjOcIdqdXCjaYLzJJRp\SCGQzDhZ5RqfmG2aX;u NWWzbIpVOjR{MkiyN|I>
Huh7 Ml3nSpVv[3Srb36gRZN{[Xl? NEWy[ms2KM7:Zz;tcC=> M3H1eFQhcA>? NImzW|li[m:uaYPo[ZMhfGinIIPlZ5JmfGmxbjDv[kAhcW62cnHj[YxtfWyjcjDBdI9D MYOyOFExODF2MB?=
Huh7 MWXGeY5kfGmxbjDBd5NigQ>? MoX5OUDPxGdxbXy= NGnJRosyKGh? M3XLTYNifXOnczDhJJNq\26rZnnjZY51KGmwY4LlZZNmKGmwIFHwc2Iu[3Knc3PlcpR{ MnPhNlQyODBzNEC=
Huh7 Mm\SSpVv[3Srb36gRZN{[Xl? NYH6N2EzPeLCk{GwxsBv\y:vbB?= MXexNkBp MVvpcoNz\WG|ZYOgRZBwSi2lcnXzZ4VvfHNid3n0bI92fCCrbnjpZol1cW6pIIPlZ5JmfGmxbh?= M33OcFI1OTByMUSw
BAECs M{HNe2Z2dmO2aX;uJGF{e2G7 NIDZT5o2KM7:Zz;tcC=> MVSwMVQhcA>? Moi3bY5lfWOnczD0bIUhemGyaXSg[IVxcG:|cHjvdplt[XSrb36gc4Yh\U6RUzDheEBU\XJzMUe5 MV2yOFA5PTJ{NR?=
Macrophages NH\2dpFHfW6ldHnvckBCe3OjeR?= MmDCO|EhyrWP NWi2bplSPiCq NXL4bINCcW6qaXLpeJMhdHWwYYPpckBqdnSncn7hcIl7[XSrb39CpC=> NGnsdWEzPDB|OUe0NC=>
Colo 205 NWfkNpY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\2PFAuPSEQvHevcWw> NEe0U|A1QCCq MofNbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5ic4XzdIVve2mxbjDjeYx1fXKnczD3bZRpKGGwIHXzeIlu[XSnZDDJR|UxKG:oII6xOUBv\y:vTB?= NEPZdnEzOzl5M{m5Oi=>
Colo 205 MUfGeY5kfGmxbjDBd5NigQ>? NUTNR3ZDOC5yMUKtNE4xOjVizsznM41N MW[xOEBl M{TIV5Jm\HWlZYOgeIhmKGOub37v[4VvcWOrdImgc4YhS2:ubzCyNFUhS1OFcx?= MmfXNlM6PzN7OU[=
Colo 205 M1rNcmFxd3C2b4Ppd{BCe3OjeR?= M4L6VVAvOSEQvHevcWw> MnzVNE0zPCCq NF:3SXdqdmS3Y3XzJIFxd3C2b4Ppd{Bw\iCFb3zvJFIxPSClZXzsd{BqdiC|dYPw[Y5{cW:wIHP1cJR2emW| MlO3NlM6PzN7OU[=
Colo 205 M{\ncGZ2dmO2aX;uJGF{e2G7 MnLvNE4xOTVizsznM41N NYS3dnRCOjRiaB?= M3TQRYlv\HWlZYOgeIhmKGW6cILld5Nqd25ib3[gSXIhe3S{ZYPzMZJmdGG2ZXSg[4Vv\XN? NX;TVZhsOjN7N{O5PVY>
Colo 205 NF\1VlNHfW6ldHnvckBCe3OjeR?= MoPpNE4xOTVizsznM41N NE\PWoMzPCCq M1zJR4lvcGmkaYTzJJRp\SCjY4Tpeol1gSCxZjDNUXB{ M{eycVI{QTd|OUm2
IBRS2 NHPpdXhHfW6ldHnvckBCe3OjeR?= NF7OVpQ2KM7:Zz;tcC=> MnS5NE42KGh? NWi0T2JJTE2VTx?= M3;OcYRqe3K3cITzJJRp\SCHUlfJR{BidmRiR3;s[4nDqA>? NYP6SVBWOjN7NkO1N|Q>
IBRS2 NGHvWm1HfW6ldHnvckBCe3OjeR?= MkP4OUDPxGdxbXy= MWmwMlUhcA>? MnqxSG1UVw>? MUjlcohidmOnczDGUWRXKGmwZnXjeIlwdg>? NFjtdlMzOzl4M{WzOC=>
HeLa MVTGeY5kfGmxbjDBd5NigQ>? MkH5NkDPxE1? MYWyJIjDqA>? NFT0Xo1ifHSnboXheIV{KHSqZTDUUmYucW6mdXPl[EB{\WO{ZYTpc44hd2ZiSVytNVU> NIjSZ3EzOzl3MEi5Ni=>
HFS  MYXGeY5kfGmxbjDBd5NigQ>? M3vVWFAuOSEQvHevcYw> M3fiWVI1KGh? MY\HUHRRKGW6cILld5Nqd25icnXhZ4hmeyCjIIDsZZRm[XViYYSgZ49v[2WwdILheIlwdnNiYYOgcI94KGG|IECuNFEhyrWpL33s NEL1NFczOzh7NE[zNy=>
HFS  MUfGeY5kfGmxbjDBd5NigQ>? NI[wXFExNjBzINM1[{9udA>? MVWyOEBp MX\pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[g[4x6[2:|cHjpcodwdGmyaXSgd5lvfGijc3Wg[4Vv\XNiYYSgOkBp MW[yN|g6PDZ|Mx?=
OVCAR-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILTW2My6oDVMUZCpO69VcLi MlOxNlTDqGh? NGDHNnNqdmS3Y3XzJIEhdG:|czDv[kBk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7wrC= M2q0[lI{QDJ4OU[0
OVCAR-3 MnvlSpVv[3Srb36gRZN{[Xl? NGLveVQy6oDVMUZCpO69VcLi NFv6W5QzPMLiaB?= M2Gx[4lv\HWlZYOgcpVkdGWjcjDkZY1i\2V? NV7PN|FYOjN6Mk[5OlQ>
OVCAR-3 M2LVNGFxd3C2b4Ppd{BCe3OjeR?= M2TRU|EuOTEEoN88US=> NH7jeoo1KGh? MWLpcoR2[2W|IITo[UBi[3SrdnH0bY9vKG:oIHHwc5B1d3Orcz3y[YxifGWmIIDyc5RmcW6| MmH3NlM5OjZ7NkS=
OVCAR-3 MU\BdI9xfG:|aYOgRZN{[Xl? Mlr2NVDDqM7:TR?= M3:5fFI1yqCq NFrDd41qdmS3Y3XzJIFkfGm4YYTpc44hd2ZiY3HzdIF{\XN? M1ixO|I{QDJ4OU[0
OVCAR-3 M{niS2Z2dmO2aX;uJGF{e2G7 NGjSWYoy6oDVMUFCpO69VQ>? NEXaWJozPMLiaB?= M3;aeIlv\HWlZYOg[Il{enWydHnvckBw\iC2aHWgcYl1d2Oqb37kdolidCC2cnHud41mdWK{YX7lJJBwfGWwdHnhcC=> M4L2S|I{QDJ4OU[0
OVCAR-3 MU\GeY5kfGmxbjDBd5NigQ>? NEfCdZYy6oDVMUFCpO69VQ>? MYKyOOKhcA>? M13ncolv\HWlZYOg[o9zdWG2aX;uJI9nKHKnYXP0bZZmKG:6eXflckB{eGWlaXXz MYCyN|gzPjl4NB?=
OVCAR-3 M1m0cWZ2dmO2aX;uJGF{e2G7 MV6x5qCUOTEEoN88US=> NITUNnYzPMLiaB?= MUXpcohq[mm2czDj[YxtKGGmaHXzbY9vKGGwZDDtbYdz[XSrb36= MXqyN|gzPjl4NB?=
MKN45 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUf5V|k{UUN3MEywMlAxOSEQvHevcYw> M4PFT|I{Pzl|M{Sy
LOVO M4jpdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnDe4JqUUN3ME2wMlEzKM7:Zz;tcC=> MW[yN|c6OzN2Mh?=
A549 NH6xSJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwMESg{txoN22u MVWyN|c6OzN2Mh?=
MDA-MB-435 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ri[2lEPTB:MD6wNFEh|rypL33s NXj1Z3RyOjN5OUOzOFI>
HepG2 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7CTWM2ODxyLkCwNUDPxGdxbXy= MXKyN|c6OzN2Mh?=
HL-60 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DaR2lEPTB:MD6wNFEh|rypL33s NFTZRXgzOzd7M{O0Ni=>

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:[5]
+ Expand
  • Cell lines: Human follicular lymphoma cell lines HF1A3, HF4.9 and HF28RA
  • Concentrations: 0 ng/mL -75 ng/mL
  • Incubation Time: 5 days
  • Method: HF1A3, HF4.9 cell viability upon the treatments is tested using double staining of cells with YO-PRO 1/PI and SYTO16/PI probes. To access cell proliferation, cells are treated with 0–100 ng/mL Brefeldin A in complete medium for 20 hours before adding 1 μCi/mL [methyl-3H]-thymidine for additional 4 hours at 37 °C. The incorporated radioactive thymidine is quantified by scintillation counting with Microbeta counter. To examine long-term effects of Brefeldin A treatment, cells are seeded at initial concentration 105 cells/mL and treated with 0-75 ng/mL Brefeldin A for up to 5 days. At the time indicated, a sample of cells is removed and viable cell number is assessed by standard Trypan Blue exclusion assay.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 4 mg/mL (14.26 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 280.36
Formula

C16H24O4

CAS No. 20350-15-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

ATPase Signaling Pathway Map

Related ATPase Products

Tags: buy Brefeldin A | Brefeldin A supplier | purchase Brefeldin A | Brefeldin A cost | Brefeldin A manufacturer | order Brefeldin A | Brefeldin A distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID